Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Cone Beam Computed Tomography with Load Technique (WBCT) Allows Correct Evaluation of Foot and Ankle Anatomy

Imaging studies are important tools in diagnosis, therapeutic decision-making, and evaluation of functional results in the area of ankle and foot performance. The most commonly used resources are conventional X-rays with load, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). The initial diagnostic investigation often uses conventional X-rays with load to reproduce the three-dimensional…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Imaging studies are important tools in diagnosis, therapeutic decision-making, and evaluation of functional results in the area of ankle and foot performance. The most commonly used resources are conventional X-rays with load, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). The initial diagnostic investigation often uses conventional X-rays with load to reproduce the three-dimensional bone relationships in the ankle and foot more accurately. However, the information acquired from this method can be limited.

Computed tomography (CT) provides for high-resolution images of the ankle and foot in different axes. Fractures, degenerative changes, bone healing, surgical planning for osteotomies, arthrodeses, and arthroplasties are all instances in which CT is the go-to imaging tool. However, it’s not a perfect option. One distinct issue with conventional CT is the fact that the technology cannot reproduce images of feet and ankles experiencing body weight load.

Over the last ten years, the cone beam computed tomography with load technique (WBCT) proved feasible for the instances mentioned above. It also offers high reproducibility of the real situation of the ankle and foot when body weight is factored in.

A review of relevant clinical studies in multiple databases from January 1999 to October 2017, titled “Weight-Bearing Computed Tomography of the Foot and Ankle: An Update and Future Direction,” analyzed the available literature on WBCT imaging in patients with foot and ankle disorders.

This review concluded that WBCT imaging allows correct evaluation of foot and ankle anatomy with the patient in a standing position, providing images with high spatial resolution, short image acquisition time, low dose of radiation, and costs which are similar to other available imaging technologies. This diagnostic tool can be used for decision making in the treatment of deformities of the ankle, hindfoot, midfoot, and forefoot.

In addition to the fact that WBCT imaging can be done with a patient in an orthostatic position, the advantages of this new technology include:

  • high resolution
  • 3D reconstruction
  • fast image acquisition
  • low radiation dose
  • small device footprint
  • lower cost than conventional CT

CurveBeam is the maker of pedCAT, which provides bilateral, weight-bearing scans of the foot and ankle.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512